학술논문

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Document Type
Article
Author
Qin, ShukuiChan, Stephen LCheng, Ann-LiiKaseb, AhmedVogel, ArndtGu, ShanzhiBai, YuxianRen, ZhenggangLin, XiaoyanChen, ZhendongJia, WeidongJin, YongdongGuo, YabingHu, XiaohuaMeng, ZhiqiangLiang, JunCheng, YingXiong, JianpingRen, HongYang, FangLi, WeiChen, YajinZeng, YongSultanbaev, AlexanderPazgan-Simon, MonikaPisetska, MargarytaMelisi, DavidePonomarenko, DmitriyOsypchuk, YuriiSinielnikov, IvanYang, Tsai-ShengLiang, XiaoChen, ChunxiaWang, LinnaZhang, MingxiangXu, LiYuan, XianglinLi, DaYing, JiererZhang, JingdongZhang, TaoGu, KangshengHe, YifuHao, PingJiang, DaZhang, ShuXing, BaocaiZhang, BaihongWang, DongZhai, XiaofengLiang, HoujieCybulska-Stopa, BozenaDvorkin, MikhailStroyakovskiy, DaniilNechaeva, MarinaYen, Chia-JuiSu, Wei-WenChen, Yen-HaoBondarenko, IgorYang, LinFang, WeijiaGomez-Martin, CarlosRyu, Min-HeeKim, Han-SangKim, Jee-HyunZarubenkov, OlegOrlova, RashidaPoddubskaya, ElenaFadeeva, NataliaMakarova, YuliaChao, YeeHung, Chao-HungNeffa, MarynaVynnychenko, OleksandrBurgoyne, AdamHao, ChunyiMohr, Raphael UDiaz-Beveridge, RobertoFeliu-Batlle, JaimeCubillo-Gracian, AntonioLee, Ann-ShingDaniele, BrunoAntonuzzo, LorenzoSangiovanni, AngeloGasbarrini, AntonioScartozzi, MarioAhn, Mi SunOh, Sung-YongOrlov, SergeyHarputluoglu, HakanOksuzoglu, BernaHsu, ChiunRau, Kun-MingKrechkovskyi, OleksandrYareshko, VladimirXiong, HenryLee, Fa-ChyiJiang, YixingGabayan, AfshinCrow, MaryVan Steenkiste, ChristopheVerset, Gontran
Source
In The Lancet 30 September-6 October 2023 402(10408):1133-1146
Subject
Primary Research
Articles
Language
ISSN
0140-6736